Identification of an LGP2-associated MDA5 agonist in picornavirus-infected cells

The RIG-I-like receptors RIG-I, LGP2, and MDA5 initiate an antiviral response that includes production of type I interferons (IFNs). The nature of the RNAs that trigger MDA5 activation in infected cells remains unclear. Here, we purify and characterise LGP2/RNA complexes from cells infected with enc...

Full description

Saved in:
Bibliographic Details
Published ineLife Vol. 3; p. e01535
Main Authors Deddouche, Safia, Goubau, Delphine, Rehwinkel, Jan, Chakravarty, Probir, Begum, Sharmin, Maillard, Pierre V, Borg, Annabel, Matthews, Nik, Feng, Qian, van Kuppeveld, Frank J M, Reis e Sousa, Caetano
Format Journal Article
LanguageEnglish
Published England eLife Sciences Publications Ltd 18.02.2014
eLife Sciences Publications, Ltd
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The RIG-I-like receptors RIG-I, LGP2, and MDA5 initiate an antiviral response that includes production of type I interferons (IFNs). The nature of the RNAs that trigger MDA5 activation in infected cells remains unclear. Here, we purify and characterise LGP2/RNA complexes from cells infected with encephalomyocarditis virus (EMCV), a picornavirus detected by MDA5 and LGP2 but not RIG-I. We show that those complexes contain RNA that is highly enriched for MDA5-stimulatory activity and for a specific sequence corresponding to the L region of the EMCV antisense RNA. Synthesis of this sequence by in vitro transcription is sufficient to generate an MDA5 stimulatory RNA. Conversely, genomic deletion of the L region in EMCV generates viruses that are less potent at stimulating MDA5-dependent IFN production. Thus, the L region antisense RNA of EMCV is a key determinant of innate immunity to the virus and represents an RNA that activates MDA5 in virally-infected cells. DOI: http://dx.doi.org/10.7554/eLife.01535.001.
Bibliography:Medical Research Council Human Immunology Unit, Radcliffe Department of Medicine, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
ISSN:2050-084X
2050-084X
DOI:10.7554/elife.01535